Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASPECT: Apadenoson for SPECT-MPI
NCT00990327Phase 3Terminated
- Sponsor
- Forest Laboratories
- Start
- Nov 2009
- Primary completion
- Apr 2012
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of apadenoson in coronary artery disease (CAD), sponsored by Forest Laboratories. Started Nov 2009; status: terminated.
02
Drugs
apadenoson
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT00990327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00990327.